SEARCH:   Advanced

Blood, 1 January 2009, Vol. 113, No. 1, pp. 18-27. Prepublished online as a Blood First Edition Paper on September 22, 2008; DOI 10.1182/blood-2008-06-165654. This Article Full Text Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2008-06-165654v1 113/1/18    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Di Nicola, M. Articles by Gianni, A. M. Search for Related Content PubMed PubMed Citation Articles by Di Nicola, M. Articles by Gianni, A. M. Related Collections Immunobiology Neoplasia Lymphoid Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study Massimo Di Nicola1, Roberta Zappasodi1, Carmelo Carlo-Stella1,2, Roberta Mortarini3, Serenella M. Pupa4, Michele Magni1, Liliana Devizzi1, Paola Matteucci1, Paola Baldassari3, Fernando Ravagnani1, Antonello Cabras5, Andrea Anichini3,*, and Alessandro M. Gianni1,2,* 1 C. Gandini Medical Oncology, Bone Marrow Transplantation Unit, Fondazione Istituti di ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan; 2 Chair of Medical Oncology, University of Milan, Milan; and 3 Human Tumor Immunobiology Unit, 4 Molecular Targeting Unit, and 5 Pathology Unit, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy Eighteen relapsed patients with measurable indolent non-Hodgkin lymphoma (NHL) were vaccinated with dendritic cells (DCs) loaded with killed autologous tumor cells. Six patients had objective clinical responses including 3 continuous complete responses (CRs) and 3 partial responses (PRs), with a median follow up of 50.5 months. Eight patients had stable disease, whereas 4 had progressive disease. Clinical responses were significantly associated with a reduction in CD4+CD25+FOXP3+ regulatory T cells, an increase in CD3–CD56dimCD16+ natural killer (NK) cells, and maturation of lymphocytes to the effector memory stage in either postvaccination peripheral blood or tumor specimen samples. In partial responding patients, vaccination significantly boosted the IFN-–producing T-cell response to autologous tumor challenge. In one HLA-A*0201+ patient who achieved CR, IL-4 release by circulating T cells in response to tumor-specific IgH-encoded peptides was also documented. Immunohistochemical analysis of tumor biopsies using biotin-conjugated autologous serum samples revealed a tumor-restricted humoral response only in the postvaccination serum from responding patients. Collectively these results demonstrate that vaccination with tumor-loaded DCs may induce both T- and B-cell responses and produces clinical benefits in indolent NHL patients with measurable disease. This study is registered with the Istituto Superiore di Sanità: http://www.iss.it with protocol number 7578-PRE 21-801. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Cancer vaccines: up, down, ... up again? Sattva S. Neelapu and Larry W. Kwak Blood 2009 113: 1-2. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020